文献速递肝病

综述:胰高血糖素样肽-1受体激动剂在非酒精性脂肪性肝炎、肥胖和糖尿病中的作用——肝病学家需要了解的内容

Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
PubMed 文献 · Aliment Pharmacol Ther · 2022-03-09

本综述汇总PubMed检索的GLP-1RAs研究,涉及2型糖尿病、肥胖及NASH。大型试验显示其降糖、减重效果,部分降低心血管事件并改善肝转氨酶;利拉鲁肽和司美格鲁肽可使约40%至60%的NASH患者获得组织学缓解,但对纤维化的显著效应尚未证实,安全性方面与胃肠道及胆囊相关不良事件相关。

要点

  • GLP-1RAs在2型糖尿病大型试验中显示有效降糖和减重,部分降低心血管事件并改善肝转氨酶。
  • 利拉鲁肽和司美格鲁肽在NASH中使约40%至60%的患者获得组织学缓解,但纤维化改善未达统计学显著。
  • GLP-1RAs与胃肠道和胆囊相关不良事件相关,Meta分析未提示急性胰腺炎或胰腺癌风险增加。

核心结论

  • 这些研究支持使用GLP-1RAs改善NASH中观察到的潜在代谢功能障碍,并提示需要进一步的长期III期试验。

研究设计与样本

  • 本综述通过PubMed检索并汇总相关研究结果。

主要发现

  • 在2型糖尿病大型试验中,GLP-1RAs显示高度有效的降糖作用并伴体重减轻,部分病例减少心血管事件并改善肝转氨酶。
  • 利拉鲁肽和司美格鲁肽在超重或肥胖且无2型糖尿病的个体中与临床相关的持续体重减轻相关。
  • 在NASH的II期试验中,利拉鲁肽减轻了与NASH发病机制相关的关键器官的代谢功能障碍、胰岛素抵抗和脂毒性。
  • 利拉鲁肽和司美格鲁肽使约40%至60%的患者获得NASH的组织学缓解,但对纤维化的统计学显著效应尚未证实。

关键数值与推荐

  • GLP-1RAs与胃肠道和胆囊相关不良事件相关,后者可能与体重减轻有关。
  • Meta分析未提示GLP-1RAs增加急性胰腺炎、胰腺癌或其他恶性肿瘤的风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-alcoholic steatohepatitis (NASH) is characterised by hepatic lipid accumulation, cell injury, inflammation and fibrosis. Insulin resistance, a hallmark of type 2 diabetes (T2D) and obesity, is a key pathogenic driver of NASH. Other than difficult-to-maintain lifestyle changes, there are no approved treatments for NASH. Due to their effects on multiple pathophysiological processes, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been tested in disorders related to insulin resistance and metabolic defects. AIMS: To summarise studies of GLP-1RAs relevant to the treatment of NASH. METHODS: PubMed searches were performed and results were compiled. RESULTS: Large trials with GLP-1RAs in T2D demonstrate highly effective glucose lowering, with body weight loss, and in some cases, reduced cardiovascular events and improved liver transaminases. The GLP-1RAs, liraglutide and semaglutide, were associated with clinically relevant, sustained body weight reduction in individuals with overweight or obesity and without T2D. In a phase II trial in NASH, liraglutide reduced metabolic dysfunction, insulin resistance and lipotoxicity in key organs associated with NASH pathogenesis. Furthermore, liraglutide and semaglutide led to histological resolution of NASH in ~40% to 60% of patients, although a statistically significant effect on fibrosis has not been confirmed. Regarding safety, GLP-1RAs are associated with gastrointestinal and gallbladder-related adverse events, with the latter perhaps related to weight loss. Meta-analyses do not indicate increased risk of acute pancreatitis, pancreatic cancer or other malignancies with GLP-1RAs. CONCLUSIONS: These studies support the use of GLP-1RAs for the improvement of underlying metabolic dysfunction observed in NASH and suggest further long-term phase III trials are warranted.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Barritt AS, Marshman E, Noureddin M, et al. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. Aliment Pharmacol Ther. 2022. PMID: 35266164. doi:10.1111/apt.16794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。